Recent news on Hyaluronidase

Halozyme Therapeutics Reports 2007 First Quarter Financial Results  -  May 10, 2007
PR Newswire (press release),The introduction by Baxter of HYLENEX recombinant (hyaluronidase human injection) for the ophthalmology market for use in enhancing the absorption and

Baxter Introduces HYLENEX For Use In Ophthalmic Surgery  -  Apr 27, 2007
eMaxHealth.com,Baxter Healthcare Corporation announced availability of HYLENEX recombinant (hyaluronidase human injection) for the ophthalmology market for use in

Brain Tumors Coax Important Support From Nearby Immune System Cells  -  Apr 16, 2007
Medical News Today (press release),Among other differences, microglia from the mouse model made more of an enzyme called hyaluronidase. Other scientists had previously identified

Halozyme and Baxter Expand Global HYLENEX Collaboration  -  Feb 19, 2007
Drug Newswire (press release),..."HYLENEX recombinant is the first and only FDA-approved recombinant human hyaluronidase drug product, and we are very proud to expand our relationship with

Halozyme Therapeutics and Baxter Present Promising Results for the ...  -  Feb 18, 2007
Drug Newswire (press release),HYLENEX recombinant is a liquid injectable formulation that includes the active pharmaceutical ingredient, recombinant human hyaluronidase (rHuPH20),

Akorn, Inc. Signs an Exclusive Supply Agreement For Hydase(TM ...  -  Jan 30, 2007
Genetic Engineering News (press release),The fact that Hydase(TM) does not contain thimerosal is an important competitive advantage over other marketed hyaluronidase drugs."

Halozyme and Baxter Expand Global HYLENEX Collaboration  -  Feb 14, 2007
Earthtimes.org14 -- Halozyme Therapeutics, Inc. and Baxter Healthcare Corporation announced today they have expanded their existing HYLENEX recombinant (hyaluronidase

Halozyme Getting Up To $65M From Expanded Baxter Alliance  -  Feb 14, 2007
BioWorld Online,Baxter, which already had rights to the existing standalone indications of the hyaluronidase-based product Hylenex, gained additional rights to use the

Halozyme and Baxter Expand Hylenex Deal  -  Feb 14, 2007
Genetic Engineering News (press release),Halozyme Therapeutics and Baxter Healthcare expanded their existing Hylenex recombinant (hyaluronidase human injection) agreements to include the use of

Results of joint Halozyme, Baxter study send both stocks up  -  Feb 14, 2007
San Diego Daily Transcript (subscription),...showing that subcutaneous administration of morphine with Hylenex recombinant (hyaluronidase human injection) accelerated the time to maximal blood

Market Report -- In Play (HTI)  -  Feb 14, 2007
MSN Money...(hyaluronidase human injection) agreements to include the use of HYLENEX recombinant with Baxter proprietary and non-proprietary small molecule drugs.

Akorn and PrimaPharm Ink Exclusive Supply Agreement  -  Jan 30, 2007
Genetic Engineering News (press release),The companies report that the total US market size for Hyaluronidase Injection is $8.6M, according to 2006 IMS data. Hydase formulation is preservative free

Biotech Day In Review: Osiris Stem Cells Treatment Has Unexpected ...  -  Feb 15, 2007
Seeking Alpha,Halozyme Therapeutics (HTI) and Baxter Healthcare (BAX) expanded their Hylenex recombinant (hyaluronidase human injection) agreements to include the use of

Roth 2007 OC Conference Presenter Profiles  -  Feb 16, 2007
American Digital Networks (press release),The company has received FDA approval for two products: Cumulase, the first and only recombinant human hyaluronidase for cumulus removal in the IVF process;

Eye on Halozyme Therapeutics  -  18 Jan 2007
Seeking Alpha,The company's first hyaluronidase enzyme, recombinant human PH20 or rHuPH20, is the platform for three different products, including a medical device,

Halozyme Therapeutics to Present at the JPMorgan 25th Annual ...  -  18 Jan 2007
Drug Newswire (press release),The company has received FDA approval for two products: Cumulase(R), the first and only recombinant human hyaluronidase for cumulus removal in the IVF

Improved Quarter for Biotech on Capital Markets ... and Financings ...  -  18 Jan 2007
PR Newswire (press release),...to apply Halozyme's Enhanze drug delivery technology based on recombinant human hyaluronidase (rHuPH20) to Roche's biological therapeutic compounds.

Recombinant respiratory antiviral now ready  -  Jan 16, 2007
BiopharmaReporter.com,The novel technology was developed by Halozyme Therapeutics and is based on recombinant human hyaluronidase (rHuPH20). According to Jonathan Lim,

New wrinkle in facial fillers  -  Jan 15, 2007
CNNBrody: Fortunately we have a dissolver for hyaluronic acid called hyaluronidase. When administered properly by a physician that is experienced in the

Halozyme Therapeutics Completes Enrollment of Enhanze Technology ...  -  Nov 28, 2006
PipelineReview.com (press release),...of a clinical trial of Enhanze(R) Technology, Halozyme's enzyme-based drug delivery platform based on recombinant human PH20 hyaluronidase (rHuPH20), intended ...

Avid and Halozyme Extend Manufacturing Agreement  -  Dec 19, 2006
Genetic Engineering News (press release),Hylenex recombinant (hyaluronidase human injection) is indicated for use as an adjuvant agent to increase the absorption and dispersion of other injected drugs ...

Avid Bioservices and Halozyme Therapeutics Extend Commercial ...  -  Dec 19, 2006
PharmaLive.com (press release),The company has received FDA approval for two products: Cumulase(R), the first and only recombinant human hyaluronidase for cumulus removal in the IVF process ...

Halozyme and Roche Enter Agreement for the Application of Enhanze ...  -  Dec 5, 2006
Yahoo! News (press release)...compounds. Enhanze Technology is Halozyme's proprietary drug delivery technology based on its recombinant human hyaluronidase (rHuPH20). ...

Roche invests in new 'molecular machete' drug delivery enhancer  -  Dec 12, 2006
In-PharmaTechnologist.com,...machete'. The novel technology was developed by Halozyme Therapeutics and is based on recombinant human hyaluronidase (rHuPH20). ...

This Inning's Still On for Halozyme  -  Dec 15, 2006
TheStreet.com (subscription),...reasons. Enhanze is Halozyme's proprietary drug-delivery technology based on its recombinant human hyaluronidase (rHuPH20). This ...

Halozyme Surges on Roche Deal  -  Dec 6, 2006
TheStreet.comEnhanze is Halozyme's drug-delivery technology based on its recombinant human hyaluronidase. Roche will pay Halozyme $20 million as an initial upfront payment. ...

Halozyme In Potential $612M Deal For Enhanze With Roche  -  Dec 6, 2006
BioWorld Online,...will have an option over the next 10 years to combine the Enhanze technology, which is based on the company's recombinant human hyaluronidase (rHuPH20), with ...

Halozyme Therapeutics Reports Third Quarter 2006 Financial Results  09 Nov 2006
...we are very excited to report that the Center for Medicare and Medicaid Services has issued a new, unique J-code (J3474, INJECTION, HYALURONIDASE, RECOMBINANT ... -Yahoo! News (press release) Rodman & Renshaw Healthcare Conference 2006 Presenter Profiles  Nov 3, 2006
The company has received FDA approval for two products: Cumulase®, the first and only recombinant human hyaluronidase for cumulus removal in the IVF process ... -Business Wire (press release), Halozyme Therapeutics Completes Enrollment Of Infuse-Morphine ...  Oct 11, 2006
Hylenex is a liquid injectable formulation that includes the active pharmaceutical ingredient, recombinant human hyaluronidase (rHuPH20). ... -Medical News Today (press release), Halozyme Therapeutics Finalizes Enrollment Of Infuse-Morphine ...  Oct 10, 2006
Hylenex is a liquid injectable formulation that includes the active pharmaceutical ingredient, recombinant human hyaluronidase. ... -Trading Markets, Herbal Remedies To Prevent Travelers Diarrhea  Sep 18, 2006
...and anti-microbial. One of the ways echinacea appears to work is by inhibiting the action of the enzyme hyaluronidase. This enzyme ... -Market-Day.net

Halozyme Therapeutics to Present at the Noble Financial Small Cap ...  Sep 19, 2006
The company has received FDA approval for two products: Cumulase(R), the first and only recombinant human hyaluronidase for cumulus removal in the IVF process ... -PR Newswire

Roche invests in new 'molecular machete' drug delivery enhancer  -  12 Dec 2006
In-PharmaTechnologist.com,The novel technology was developed by Halozyme Therapeutics and is based on recombinant human hyaluronidase (rHuPH20). Called Enhanze, the enzyme technology

Halozyme and Roche Enter Agreement for the Application of Enhanze ...  -  Dec 6, 2006
PharmaLive.com (press release),Enhanze Technology is Halozyme's proprietary drug delivery technology based on its recombinant human hyaluronidase (rHuPH20). rHuPH20 is an analogue of a

Halozyme Therapeutics Completes Enrollment of Enhanze Technology ...  -  Nov 28, 2006
PipelineReview.com (press release),As a spreading agent, hyaluronidase has traditionally been used to accelerate the delivery of drugs and fluids, including local anesthetics,

Halozyme Surges on Roche Deal  -  Dec 6, 2006
TheStreet.comEnhanze is Halozyme's drug-delivery technology based on its recombinant human hyaluronidase. Roche will pay Halozyme $20 million as an initial upfront

Halozyme In Potential $612M Deal For Enhanze With Roche  -  Dec 6, 2006
BioWorld Online,Roche also will have an option over the next 10 years to combine the Enhanze technology, which is based on the company's recombinant human hyaluronidase

Halozyme Therapeutics to Present at the Lazard Capital Markets ...  -  Nov 20, 2006
Drug Newswire (press release),The company has received FDA approval for two products: Cumulase(R), the first and only recombinant human hyaluronidase for cumulus removal in the IVF

Halozyme Therapeutics to Present at the Roth 2006 New York ...  29 Aug 2006
The company has received FDA approval for two products: Cumulase®, the first and only recombinant human hyaluronidase for cumulus removal in the IVF process ... -Yahoo! News

Halozyme Therapeutics Reports Second Quarter 2006 Financial ...  Aug 10, 2006
Meeting in Washington, DC The results support the safety profile for Chemophase, a high dose formulation of the recombinant human hyaluronidase enzyme, rHuPH20 ... -MSN Money

Halozyme Therapeutics Initiates First Enhanze Technology Clinical ...  Aug 8, 2006
...- Study to Explore the Effects of Recombinant Human PH20 Hyaluronidase on the Pharmacokinetics of a Commercially Available Large Molecule Protein Therapeutic ... -PR Newswire

Halozyme Therapeutics Initiates First Enhanze Technology Clinical ...  Aug 9, 2006
...in a clinical trial of Enhanze(R) Technology, Halozyme's enzyme-based drug delivery platform based on recombinant human PH20 hyaluronidase (rHuPH20), intended ... -Medical News Today

Halozyme Begins First Enhanze Drug-Enhancement Trial  Aug 9, 2006
...molecule protein therapeutic. Halozyme's Enhanze Technology is based on recombinant human PH20 hyaluronidase (rHuPH20). This current ... -International News Service

Germany Approves Echinacea as Natural Skin Care Treatment  Aug 15, 2006
Echinacea prevents the formation of hyaluronidase – an enzyme that destroys the cell walls that prevent penetration of bacteria and viruses, its ... -The Open Press

Alaska sets nonstop service to SF  Aug 9, 2006
...of three patients in a clinical trial of Enhanze technology, the company's enzyme-based drug-delivery platform based on recombinant human PH20 hyaluronidase. ... -San Diego Union Tribune

Reactions to insect stings can usually be treated at home  Aug 11, 2006
...reactions such as anaphylaxis. Other enzymes in the venom, such as hyaluronidase, spread the reaction through the tissue. The result is ... -Nashua Telegraph (subscription)

Halozyme Therapeutics Reveals New Results From Hyaluronidase ...  Jul 12, 2006
...(HTI | charts | news | PowerRating), a biopharmaceutical company, revealed new findings for its HTI-101, hyaluronidase enzyme candidate. ... -Trading Markets

Halozyme Therapeutics Announces New Studies From HTI-101 Presented ...  Jul 15, 2006
...and commercializing recombinant human enzymes, today announced the presentation of new findings for HTI-101, its second hyaluronidase enzyme candidate, at the ... -Medical News Today

Halozyme and Baxter Announce Availability of Hylenex for ...  Jun 27, 2006
...and Baxter Healthcare Corporation announced today the availability of Hylenex, a liquid injectable formulation of recombinant human hyaluronidase, in the ... -Finanzen.net

FDA Sends PrimaPharm Letter Over Hydase Sales Aids  Jun 30, 2006
Hyaluronidase should not be used to reduce the swelling of bites or stings. Hyaluronidase should not be applied directly to the cornea. ... -PharmaLive.com

Halozyme Presents Results From New Studies On HTI-101 - Quick ...  Jul 12, 2006
Inc. (HTI | charts | news | PowerRating) said it has presented the new findings for its second hyaluronidase enzyme candidate HTI. ... -Trading Markets

Concurrent Expression of Hyaluronan Biosynthetic and Processing ...  Jun 30, 2006
HAS3. Combined detection of HA and the HA processing hyaluronidase enzyme Hyal1 in prostate tumors correlates with poor outcome. ... -Am J Pathology (subscription)

Avastin cancer drug test halted  Jun 28, 2006
San Diego-based Halozyme Therapeutics said that its product Hylenex, a liquid injectable formulation of recombinant human hyaluronidase, is on the market in ... -San Diego Union Tribune

Search for Biomarkers of Aggressiveness in Bladder Cancer  Jun 28, 2006
...and adenovirus receptor), cytokeratins, telomerase, survivin, HSP70, matrix metalloproteinases, nuclear matrix protein 22, hyaluronic acid, and hyaluronidase. ... -UroToday

Halozyme Therapeutics to Present at the Jefferies Life Sciences ...  Jun 21, 2006
The company has received FDA approval for two products: Cumulase(R), the first and only recombinant human hyaluronidase for cumulus removal in the IVF process ... -Drug Newswire



Halozyme Therapeutics Reports First Quarter 2006 Financial Results  May 10, 2006
...completion of patient enrollment for the Phase I clinical trial of Chemophase, a high dose formulation of the recombinant human hyaluronidase enzyme, rHuPH20 ... - PR Newswire

Halozyme Therapeutics Announces 22% Increase in IVF ICSI ...  May 4, 2006
The paper, "Comparison of bovine- and recombinant human-derived hyaluronidase with regard to fertilization rates and embryo morphology in a sibling oocyte model ... - PR Newswire

ProMetic Announces First Quarter 2006 Financial Results Important ...  May 12, 2006
...(Amex: HTI) had received US Food and Drug Administration (FDA) approval for Hylenex recombinant (hyaluronidase human injection), for use as an adjuvant agent ... - Market Wire

ISTA Pharmaceuticals, Inc. Reports First Quarter 2006 Financial ...  May 8, 2006
IMS Data.) - In January, ISTA announced the acceptance by the EMEA of ISTA's European Marketing Application for Vitragan(TM) (Ovine Hyaluronidase) for the ... - Yahoo! News

Halozyme Therapeutics to Present at the Rodman & Renshaw 3rd ...  May 9, 2006
The company has received FDA approval for two products: Cumulase(R), the first and only recombinant human hyaluronidase for cumulus removal in the IVF process ... - PR Newswire

Halozyme Therapeutics Initiates Chemophase Phase I/IIa Clinical ...  Apr 26, 2006
Meeting in Washington, DC The results support the safety profile for Chemophase, a high dose formulation of the recombinant human hyaluronidase enzyme, rHuPH20 ... - PharmaLive.com





Halozyme Therapeutics Presents Preclinical and Phase I ...  Apr 4, 2006
Meeting in Washington, DC The results support the safety profile for Chemophase, a high dose formulation of the recombinant human hyaluronidase enzyme, rHuPH20 ... - PR Newswire

Halozyme Therapeutics Reports Fourth Quarter and Year End 2005 ...  Mar 23, 2006
The approval of Hylenex recombinant (hyaluronidase human injection) by the US Food and Drug Administration (FDA) in December 2005 for use as an adjuvant ... - PR Newswire

Halozyme Therapeutics Says Pre-clinical, Pharmacokinetic Data ...  Apr 4, 2006
...data from the Phase I clinical trial support the safety profile of Chemophase, a high-dose formulation of the recombinant human hyaluronidase enzyme, rHuPH20. ... - Trading Markets

Halozyme Therapeutics to Present Preclinical, Toxicology and Phase ...  Mar 28, 2006
Pre-clinical data on the pharmacology and toxicology of rHuPH20, a recombinant human hyaluronidase, with mitomycin will be presented along with clinical data ... - PharmaLive.com

Halozyme Therapeutics to Present Preclinical, Toxicology and Phase ...  Mar 28, 2006
...at the AACR Annual Meeting in Washington, DC Pre-clinical data on the pharmacology and toxicology of rHuPH20, a recombinant human hyaluronidase, with mitomycin ... - PR Newswire

Halozyme Therapeutics to Hold 2005 Fourth Quarter and Year End ...  Mar 20, 2006
The company has received FDA approval for two products: Cumulase(TM), the first and only recombinant human hyaluronidase for cumulus removal in the IVF process ... - PR Newswire

Halozyme completes enrollment in bladder cancer trial  Mar 7, 2006
...decision would also see Chemophase join Halozyme Therapeutics' two currently approved products, Cumulase, the only recombinant human hyaluronidase for cumulus ... - Pharmaceutical Business Review



Halozyme Therapeutics and Baxter Release Results From the INFUSE ...  Feb 8, 2006
Hylenex is a liquid injectable formulation that includes the active pharmaceutical ingredient, recombinant human hyaluronidase (rHuPH20), which is approved by ... - PharmaLive.com,

Halozyme Therapeutics and Baxter Release Results From the INFUSE ...  Feb 8, 2006
Hylenex is a liquid injectable formulation that includes the active pharmaceutical ingredient, recombinant human hyaluronidase (rHuPH20), which is approved by ... - Yahoo! News

Halozyme Therapeutics Initiates Clinical Trial of Subcutaneous ...  Feb 2, 2006
Hylenex is a liquid injectable formulation that includes the active pharmaceutical ingredient, recombinant human hyaluronidase (rHuPH20). ... - PR Newswire

ISTA Pharmaceuticals Announces Acceptance of ISTA's European ...  Jan 12, 2006
...accepted for review ISTA's centralized Marketing Authorisation Application (MAA) seeking European market approval of Vitragan(TM) (Ovine Hyaluronidase) for the ... - PR Newswire

Research Supports Effectiveness Of Biocell Collagen II(r) In ...  Jan 19, 2006
ANAHEIM, CA, January 19, 2006 - A new bioassay report states the effectiveness of BioCell Collagen II(r) with hyaluronic acid (HA) in inhibiting hyaluronidase. ... - NPIcenter

Halozyme advances trial of absorption agent  Jan 25, 2006
The company is testing Hylenex, a liquid injectable formulation that includes the active pharmaceutical ingredient recombinant human hyaluronidase (rHuPH20). ... - Pharmaceutical Business Review

Bioassay supports skin benefit of BioCell ingredient  Jan 20, 2006
Degradation of HA is thought to be the work of an enzyme called hyaluronidase. The study, commissioned by AIBMR Life Sciences, showed ... - NutraIngredients-usa.com

ISTA's eye treatment under EU review  Jan 12, 2006
12 Jan 2006, 17:44 GMT - Vitragan is ISTA's proprietary formulation of highly purified ovine hyaluronidase, which is commonly known in the US as vitrase. ... - Pharmaceutical Business Review

ProMetic Product Used in the Manufacture of an FDA-Approved ...  Jan 16, 2006
...of PLI's subsidiary ProMetic BioSciences Ltd, has received US Food and Drug Administration (FDA) approval for Hylenex recombinant (hyaluronidase human injection ... - CCNMatthews

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional